Familial amyloid polyneuropathy.
Adams D, Cauquil C, Labeyrie C.
Curr Opin Neurol. 2017 Oct;30(5):481-489. doi: 10.1097/WCO.0000000000000476.
Familial amyloid polyneuropathy.
Barreiros AP, Galle PR, Otto G.
Dig Dis. 2013;31(1):170-4. doi: 10.1159/000347214. Epub 2013 Jun 17.
Familial amyloid polyneuropathy.
Planté-Bordeneuve V, Said G.
Lancet Neurol. 2011 Dec;10(12):1086-97. doi: 10.1016/S1474-4422(11)70246-0.
Familial amyloid polyneuropathy.
Reilly MM, King RH.
Brain Pathol. 1993 Apr;3(2):165-76. doi: 10.1111/j.1750-3639.1993.tb00741.x.
Amyloid polyneuropathy.
SULLIVAN JF, TWITCHELL TE, GHERARDI GJ, VANDERLAAN WP Jr.
Neurology. 1955 Dec;5(12):847-55. doi: 10.1212/wnl.5.12.847.
Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
Adams D, Beaudonnet G, Adam C, Lacroix C, Théaudin M, Cauquil C, Labeyrie C.
Rev Neurol (Paris). 2016 Oct;172(10):645-652. doi: 10.1016/j.neurol.2016.08.007. Epub 2016 Sep 21.
Transthyretin familial amyloid polyneuropathy: an update.
Plante-Bordeneuve V.
J Neurol. 2018 Apr;265(4):976-983. doi: 10.1007/s00415-017-8708-4. Epub 2017 Dec 16.
[Familial amyloid polyneuropathy].
Yamashita T, Ando Y, Uchino M.
Brain Nerve. 2011 Jun;63(6):583-95.
Recent advances in familial amyloid polyneuropathy.
Freeman R, Barroso F.
Curr Opin Neurol. 2015 Oct;28(5):494-9. doi: 10.1097/WCO.0000000000000244.
Patisiran for the treatment of patients with familial amyloid polyneuropathy.
Rizk M, Tüzmen S.
Drugs Today (Barc). 2019 May;55(5):315-327. doi: 10.1358/dot.2019.55.5.2958475.
